Canadian Cannabis Stocks “Naturally” Changing the World; New Approaches to Anxiety and Sleep Disorders, Pain Treatment, Drug Delivery and Food Supplements
POINT ROBERTS, Wash. and DELTA, British Columbia, June 13, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source and investor resource covering cannabis stocks issues a sector news alert on Canadian cannabis stocks introducing natural and organic alternatives to key health issues using cannabinoids. A global revolution is taking place in healthcare, life sciences and the food and beverage industry with applications including treatment of anxiety and sleep disorders, pain management, drug delivery and food supplements.
The global landscape is changing so rapidly that in some instances, cannabis is now taking on traditional healthcare at par. Troy Dayton, CEO and Founder of the Arcview Group, told Investor Ideas at the recently held Arcview Investor Forum in Vancouver B.C., “What’s happening in Germany is very interesting. They are going to have medical cannabis covered by insurance. Cannabis is actually going to be on the same playing field as pharmaceuticals.”
One Canadian stock ready to capitalize on that is Aphria Inc. ( Quote ). In May, Aphria announced that its wholly-owned subsidiary Nuuvera Deutschland GmbH acquired a 25.1% interest in Berlin-based Schöneberg Hospital (“Schöneberg” or the “Hospital”). The acquisition facilitates Deutschland’s long-term strategy to educate German physicians and patients and advance evidence that supports the effectiveness of medical cannabinoids. It is also the first step in Deutschland’s plans to build and operate pain treatment centers throughout Germany. The acquisition is valued at €1.2 million.
“With our partnership with Schöneberg, we are laying the groundwork to be at the forefront of medical services,” said Hendrik Knopp, Managing Director of Deutschland. “We are focused on bringing a patient-centric approach to medical cannabis in Germany, improving awareness and education of the therapeutic properties of medical cannabis among doctors and patients.”
“The German market is among the most attractive opportunities for medical cannabis in the world, and this deal is an important step towards furthering Deutschland’s presence in the country,” said Vic Neufeld, CEO of Aphria. “Like the clinic model in the Canadian market, these pain treatment centers will serve an invaluable purpose in supporting and educating patients, physicians and the German public in the treatment of pain, including, among other treatments, through the use of medical cannabis. We are continuing to advance our international strategic plans with investments such as this that lay the foundation for long-term sustained growth in every market in which we operate.”Full news: https://ca.finance.yahoo.com/news/aphrias-german-subsidiary-nuuvera-deutschland-120000511.html
Another Canadian company entering the sector has its origins in natural remedies in healthcare and life sciences, EVITRADE Health Systems Corp. (CSE:EVA) (OTCQB:AXHLF). ( http://www.evahealthsystems.com/ )
According to their website: “The Company is investigating the health effects of various natural remedies on the health of consumers either alone or in conjunction with other elements. In focus are various plant-based products that are targeted to relieve symptoms such as anxiety, sleeplessness, chronic inflammation, fatigue and high cholesterol. Initial projects will include Astaxanthin, Spirulina and eventually, Cannabinoids.”
Looking forward, the Company sees additional potential uses for cannabinoids to include addiction treatment, anti-inflammatory treatment and epilepsy.
On May 30, 2018, EVITRADE ( CSE:EVA ) ( OTCQB:AXHLF ) announced that it had signed a revised Letter of Intent with Cantech Molecular Research Inc. The soon-to-be acquired Cantech and/or Cantech Intellectual Property (“IP”) specializes in systems for the manufacture of highly advanced plants grown through selective breeding (also known as cultivars) and the production of quality pharmaceutical products for use in agriculture and medicine.
“With this transaction, the Company is looking to add yet another valuable and versatile asset in its ongoing bid to become an influential player in the rapidly growing plant-based pharmaceutical business”, said C.K. Cheung, CEO.Full news: https://webfiles.thecse.com/2018-05-30_EVA-Cantech_LOI_-_FINAL_CK.pdf?cSeonQGdbglpChHjn2lNLdy__8Lbr63Q
On May 31, 2018 EVITRADE announced that it made a voluntary ticker symbol change application with FINRA for the Company’s quotation on the OTC Markets OTCQB® Venture Market. The symbol is expected to better reflect the corporate name and its new image. The Company also recently launched a new website to reflect its expansion in the medical technology, health and life sciences markets.
EVITRADE continued to offer some insight as to where it is focussing with the announcement on June 11, 2018; “EVITRADE To Bring Blockchain Technology to the Hemp Industry”. The Company has signed a Letter of Intent with Veri-Medical Systems Inc. (“Verimed” or the “Company”) to potentially acquire the Company which has created a blockchain based “seed-to-sale” protocol focussed on enhancing the integrity of the sale of Hemp based products such as cannabidiol (“CBD”).
Cannabis and cannabinoids also offer a new approach to drug delivery and a Kelowna based company, Lexaria Bioscience Corp. ( Quote ), has developed and out-licensed its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.
On May 31, 2018, Lexaria announced that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (“NSAIDs”), phosphodiesterase (“PDE5”) inhibitors and other active pharmaceutical ingredients.
This proposed structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each. It is expected that Lexaria’s patented DehydraTECHTM technology will be utilized by both subsidiaries.
Lexaria recently announced lab test results related to delivery of nicotine through the gastrointestinal tract and superior nicotine absorption in animal blood plasma.
Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, NSAIDs, PDE5 inhibitors, nicotine and other molecules.Full news: https://ca.finance.yahoo.com/news/lexaria-bioscience-corp-structures-nicotine-102500495.html
Natural and organic food trends are on the rise globally; all you have to do is look at the success of Whole Foods, eventually bought out by Amazon. Hemp’s history with food goes back to the origins of man and now has a resurgence - thanks to the global legalization trends and new technology.
For more than 12 years Hempco Food and Fiber Inc. ( Quote) has been a trusted and respected pioneer, innovator and provider of premier hemp-based foods and hemp nutraceuticals. Aurora Cannabis Inc. ( Quote ) saw the value of the company and owns over 50% of the Company.
Hempco Food and Fiber recently announced its growth and expansion plans. The Company has signed a distribution agreement with Tree of Life, the United Kingdom’s leading wholesale distributor of natural and organic products. Tree of Life serves more than 1,200 retailers in the UK and more than 30 countries worldwide. The agreement provides Hempco with significantly increased market reach through Tree of Life’s large footprint and share of shelf space in the health food sector.
The relationship with Tree of Life was driven in part by the recognition of the strong momentum hemp products continue to experience in the health food market due to its beneficial properties, such as omega 3′s and high plant-based protein content.
The new Planet Hemp Organic Hemp Seed Oil + CBD Food Supplement line was successfully launched at Europe’s biggest Natural and Organic products tradeshow on April 22-23, 2018. The show, visited by ten thousand delegates, including distributors and retailers, was very successful for the Company, both in terms of raising visibility and in generating commercial traction. Reception of the new product line was positive, with new orders received.
The Planet Hemp Organic Hemp Seed Oil + CBD Food Supplement product line, available in Original, Mint and Orange, is the only product approved by the Vegan and Vegetarian Societies. This is a rapidly growing segment of the market, and this validation creates significant differentiating power for Hempco.
About Investorideas.com - News that Inspires Big Ideas Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.
Investorideas.com cannabis/marijuana and hemp news and investing content includes potcastsCM – podcasts featuring cannabis news and stocks to watch plus insight from thought leaders and experts. Cannabis content also includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com, the 420 Cannabis Investor ideas directory www.420cannabisinvestorideas.com, and Global Cannabis Investing at www.Globalcannabisinvesting.com.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country. Disclosure: Investorideas was compensated for this tag article to include EVITRADE Health Systems Corp. - learn more about costs and services http://www.investorideas.com/News-Upload/
Contact Investorideas.com 800-665-0411